Clinical Trial Update: Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms

View source ↗

Summary

A clinical trial evaluating imatinib response in chronic-phase chronic myeloid leukemia as a function of Abl polymorphisms has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nīmes | Conditions: Leukemia, Myeloid, Chronic-Phase | Status: WITHDRAWN